Latest News

ASCO Presentation Provides Real World Evidence of Brexu-cel’s Efficacy in R/R B-ALL
ASCO Presentation Provides Real World Evidence of Brexu-cel’s Efficacy in R/R B-ALL

June 2nd 2023

In a real-world population of patients with relapsed or refractory B-cell acute lymphoblastic leukemia, modest efficacy was demonstrated with brexucabtagene autoleucel.

Obe-cel Induces 76% CR/CRi Rate With Compelling MRD Negativity in R/R B-ALL
Obe-cel Induces 76% CR/CRi Rate With Compelling MRD Negativity in R/R B-ALL

June 2nd 2023

FDA Approves Nelarabine Injection for the Treatment of T-ALL and T-LBL
FDA Approves Nelarabine Injection for the Treatment of T-ALL and T-LBL

March 7th 2023

Ponatinib Demonstrates Deep and Durable Responses vs Imatinib in Ph+ ALL
Ponatinib Demonstrates Deep and Durable Responses vs Imatinib in Ph+ ALL

February 27th 2023

Ibrutinib-Treated Patients Show Higher Risk of Developing Cardiotoxicity
Ibrutinib-Treated Patients Show Higher Risk of Developing Cardiotoxicity

February 23rd 2023

More News